Cencora Acquires Retina Consultants of America to Strengthen Specialty Healthcare Services
- Cencora acquires Retina Consultants of America for $4.4 billion, gaining 85% ownership to enhance specialty healthcare services.
- The acquisition aligns with Cencora's strategy to improve health outcomes and leverage RCA's expertise in retina care.
- Cencora projects increased earnings per share for 2025, reflecting confidence in RCA's impact on growth and service delivery.
Cencora Expands Specialty Healthcare Footprint Through Acquisition of Retina Consultants of America
Cencora, Inc., a leading global pharmaceutical solutions provider, bolsters its position in specialty healthcare with the acquisition of Retina Consultants of America (RCA). This significant transaction, valued at approximately $4.4 billion, grants Cencora about 85% ownership of RCA, a prominent management services organization (MSO) dedicated to supporting retina specialists. By integrating RCA into its operations, Cencora aims to enhance its suite of management services and expand its leadership within the specialty services sector. Notably, RCA's physicians and management team will maintain a minority equity stake, ensuring their continued involvement and commitment to the organization’s mission.
The acquisition aligns with Cencora's strategic focus on improving health outcomes and delivering value to stakeholders, including patients and healthcare providers. With RCA's established reputation and expertise in retina care, Cencora expects to leverage its existing infrastructure to optimize service delivery and expand its offerings in the specialty healthcare market. This move not only strengthens Cencora's operational capabilities but also reinforces its commitment to fostering healthier futures through innovative healthcare solutions.
Following the acquisition, Cencora has revised its financial outlook for the fiscal year 2025, projecting adjusted diluted earnings per share (EPS) to range between $15.15 and $15.45—an increase from its previous estimate of $14.80 to $15.10. This upward revision reflects Cencora's confidence in RCA's contributions to its ongoing growth, particularly within its U.S. Healthcare Solutions segment. With more than 46,000 employees and annual revenues exceeding $290 billion, Cencora continues to emphasize its role as a vital partner for pharmaceutical innovators, ensuring efficient access to therapies and reliable delivery of healthcare products.
In addition to its acquisition strategy, Cencora remains committed to enhancing its operational capabilities and expanding its service portfolio. The company ranks #10 on the Fortune 500 and #18 on the Global Fortune 500, underscoring its significant impact within the pharmaceutical industry. As it integrates RCA into its business model, Cencora looks to solidify its market position and further its mission of advancing healthcare outcomes globally. The collaboration between Cencora and RCA serves as a testament to the growing importance of specialized healthcare services in meeting the evolving demands of patients and providers alike.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

